Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCareOregon Vyvgart Hytrulo Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentCareOregonPolicy N/A

    Vyvgart Hytrulo Prior Authorization

    Customize your policy alerts

    Sign up for all careoregon policy alerts

    Know when careoregon releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization for Vyvgart Hytrulo in generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, including diagnostic documentation, specialist involvement, prior treatment requirements, and continuation criteria.

    Policy Summary
    PayerCareOregon
    PolicyVyvgart Hytrulo Prior Authorization
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 1, 2026
    Next Review DateNot specified
    Key ActionSubmit prior authorization documentation showing required prior therapy failures or contraindications and why IV Vyvgart cannot be used.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2Covered clinical indications
    6 monthsApproval length
    4Required prior therapies for myasthenia gravis
    NeurologistRequired prescriber specialty
    >2 months

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Minimum CIDP duration

    Coverage Criteria

    Initial therapy — generalized myasthenia gravis

    Covered for initial authorization when all of the following are met.

    Initial generalized myasthenia gravis criteria

    • Specialist and diagnosis: Prescribed by or in consultation with a neurologist; generalized myasthenia gravis with clinical classification II to IV.Clinical classification II to IV
    • Baseline assessment: A baseline Myasthenia Gravis Activities of Daily Living (MG-ADL) score has been obtained.Baseline MG-ADL score obtained
    • Prior therapy

      • Required therapies: Pyridostigmine and corticosteroids must both have been tried and failed.
      • Additional immunosuppressive therapies

        • Azathioprine: Tried and failed azathioprine.
        • Mycophenolate: Tried and failed mycophenolate.
        • Cyclosporine: Tried and failed cyclosporine.
        • Tacrolimus: Tried and failed tacrolimus.
    • IV Vyvgart alternative: Medical record documentation shows clinical failure, intolerance, contraindication, or another valid medical reason why IV Vyvgart cannot be used.

    Continuation therapy — myasthenia gravis

    Continuation approval requires documented response to therapy.

    Myasthenia gravis continuation criterion: Documentation demonstrates a clinically significant and meaningful response to therapy.Clinically significant and meaningful response

    Initial therapy — CIDP

    Covered for CIDP when all of the following are met.

    CIDP criteria

    • Specialist and indication: Prescribed by or in consultation with a neurologist; Vyvgart Hytrulo is indicated or supported for treating chronic inflammatory demyelinating polyneuropathy (CIDP).
    • Disease duration: The condition has persisted for longer than 2 months.>2 months
    • Objective baseline assessment: Baseline strength and weakness are documented using an objective clinical measure, such as INCAT, MRC, 6-minute timed walking test, Rankin, or Modified Rankin.Objective baseline measure documented

    Continuation therapy — CIDP

    Continuation approval requires improvement from baseline.

    CIDP continuation criterion: There is improvement from baseline strength and weakness using an objective clinical measuring tool.Improvement from baseline

    Clinical Documentation and Coding Details

    CIDP duration
    ConditionChronic inflammatory demyelinating polyneuropathy (CIDP)
    Required durationLonger than 2 months
    Authorization requirementThe condition must have persisted for longer than 2 months
    CIDP objective assessment
    Baseline strengthMust be documented before treatment
    Baseline weaknessMust be documented before treatment
    Objective measuresINCAT, MRC, 6-minute timed walking test, Rankin, or Modified Rankin

    Provider Actions and Authorization Requirements

    Prior Authorization

    Myasthenia Gravis Initial Authorization

    Prior authorization is required for Vyvgart Hytrulo for generalized myasthenia gravis. Initial authorization is limited to 6 months when the applicable criteria are met.

    • Product: Vyvgart Hytrulo
    • Therapy stage: Initial authorization
    • Approval length: 6 months
    • Guideline type: Prior authorization
    Prior Authorization

    CIDP Authorization

    Prior authorization is required for Vyvgart Hytrulo for chronic inflammatory demyelinating polyneuropathy (CIDP). Authorization is limited to 6 months when the applicable criteria are met.

    • Product: Vyvgart Hytrulo
    • Approval length: 6 months
    • Guideline type: Prior authorization

    Policy Background

    Vyvgart Hytrulo is reviewed under prior authorization for two covered indications: generalized myasthenia gravis with clinical classification II to IV and chronic inflammatory demyelinating polyneuropathy (CIDP) that has persisted for longer than 2 months. Initial approval requires neurologist involvement, condition-specific diagnostic documentation, appropriate prior treatment experience, and documentation of why IV Vyvgart cannot be used. Approval is for 6 months.

    For continuation, documentation must show a clinically significant and meaningful response for generalized myasthenia gravis or improvement from baseline strength and weakness using an objective clinical measuring tool for CIDP.

    Definitions

    Generalized myasthenia gravis classification
    ConditionGeneralized myasthenia gravis
    Clinical classificationClass II to IV
    Coverage definitionGeneralized myasthenia gravis with clinical classification II to IV
    Baseline MG-ADL score
    AssessmentMyasthenia Gravis Activities of Daily Living (MG-ADL) score
    TimingObtained before treatment
    Authorization requirementA baseline MG-ADL score must be obtained

    Initial Therapy Criteria

    Initial therapy — generalized myasthenia gravis

    Initial authorization for generalized myasthenia gravis requires all of the following.

    Initial generalized myasthenia gravis criteria

    • Specialist and diagnosis: Prescribed by or in consultation with a neurologist; generalized myasthenia gravis with clinical classification II to IV.Clinical classification II to IV
    • Baseline assessment: A baseline Myasthenia Gravis Activities of Daily Living (MG-ADL) score has been obtained.Baseline MG-ADL score obtained
    • Prior therapy

    Continuation Criteria

    Myasthenia gravis continuation

    Continuation approval for myasthenia gravis requires all of the following.

    Myasthenia gravis response: Documentation demonstrates a clinically significant and meaningful response to therapy.Clinically significant and meaningful response

    CIDP continuation

    Continuation approval for CIDP requires all of the following.

    CIDP response: There is improvement from baseline strength and weakness using an objective clinical measuring tool.Improvement from baseline

    Step Therapy Requirements

    StepRequired prior therapyRequirement
    1Pyridostigmine and corticosteroidsTried and failed both therapies, plus at least two of azathioprine, mycophenolate, cyclosporine, or tacrolimus.
    StepRequired prior therapyRequirement
    1Corticosteroids and IVIGFailure of or contraindication to both therapies.

    Quantity Limits

    Quantity limit
    ProductVyvgart Hytrulo
    Quantity limit6
    Limit basisPer course; months per approval
    Policy Summary
    PayerCareOregon
    PolicyVyvgart Hytrulo Prior Authorization
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 1, 2026
    Next Review DateNot specified
    Key ActionSubmit prior authorization documentation showing required prior therapy failures or contraindications and why IV Vyvgart cannot be used.
    SourceLink
    On This Page
    Coverage CriteriaClinical Documentation and Coding DetailsProvider Actions and Authorization RequirementsPolicy BackgroundDefinitionsInitial Therapy CriteriaContinuation CriteriaStep Therapy RequirementsQuantity Limits
    Diagnostic support: Electrophysiologic findings support the diagnosis and rule out other conditions that may not respond to Vyvgart Hytrulo treatment.Supportive electrophysiologic findings
  1. Prior therapy and IV Vyvgart alternative

    • Corticosteroids: Failure of or contraindication to corticosteroids.
    • IVIG: Failure of or contraindication to IVIG.
    • IV Vyvgart alternative: Medical record documentation shows clinical failure, intolerance, contraindication, or another valid medical reason why IV Vyvgart cannot be used.
  2. Step Therapy

    Myasthenia Gravis Prior Therapy

    For initial myasthenia gravis authorization, documentation must show that the member has tried and failed the required therapies, including pyridostigmine, corticosteroids, and at least two specified immunosuppressive therapies.

    • Failed or attempted pyridostigmine
    • Failed or attempted corticosteroids
    • Failed or attempted at least two of: azathioprine, mycophenolate, cyclosporine, or tacrolimus
    • Medical records must document clinical failure, intolerance, contraindication, or another valid medical reason why IV Vyvgart cannot be used
    Step Therapy

    CIDP Prior Therapy

    CIDP authorization requires failure of or contraindication to both corticosteroids and IVIG, along with documentation of clinical failure, intolerance, contraindication, or another valid medical reason why IV Vyvgart cannot be used.

    • Failure of or contraindication to corticosteroids
    • Failure of or contraindication to IVIG
    • Document why IV Vyvgart cannot be used
    Documentation Required

    Myasthenia Gravis Documentation

    The request must be prescribed by or made in consultation with a neurologist and must include documentation supporting generalized myasthenia gravis, the required clinical classification, and a baseline MG-ADL score.

    • Prescribed by or in consultation with a neurologist
    • Generalized myasthenia gravis with clinical classification II to IV
    • Baseline Myasthenia Gravis Activities of Daily Living (MG-ADL) score obtained
    • Supporting medical record documentation, including the required treatment history and reason IV Vyvgart cannot be used
    Documentation Required

    CIDP Documentation

    The request must be prescribed by or made in consultation with a neurologist and must document the required CIDP diagnosis, duration, objective baseline strength and weakness findings, and supporting electrophysiologic evidence.

    • Prescribed by or in consultation with a neurologist
    • Vyvgart Hytrulo is indicated or supported for treating CIDP
    • Condition has persisted for longer than 2 months
    • Baseline strength and weakness documented with an objective measure, such as INCAT, MRC, 6-minute timed walking test, Rankin, or Modified Rankin
    • Electrophysiologic findings support CIDP and rule out other conditions that may not respond to Vyvgart Hytrulo
    Documentation Required

    Continuation Documentation

    Continuation authorization requires documentation of a clinically meaningful response or improvement from baseline while receiving Vyvgart Hytrulo.

    • For myasthenia gravis: clinically significant and meaningful response to therapy
    • For CIDP: improvement from baseline strength and weakness using an objective clinical measuring tool
    Denial Risk

    Myasthenia Gravis Criteria Not Met

    Myasthenia gravis authorization is not supported when the required classification, baseline scoring, treatment history, neurologist involvement, or other approval requirement is missing or unmet.

    • Not generalized myasthenia gravis with clinical classification II to IV
    • Baseline MG-ADL score not obtained
    • Required prior therapies have not been tried and failed, or an acceptable exception is not documented
    • No neurologist prescription or consultation
    • Required documentation of why IV Vyvgart cannot be used is absent or insufficient
    Denial Risk

    CIDP Criteria Not Met

    CIDP authorization is not supported when the required duration, objective findings, electrophysiologic evidence, prior therapy, neurologist involvement, or other approval requirement is missing or unmet.

    • Condition has not persisted longer than 2 months
    • Objective baseline strength and weakness findings are not documented
    • Electrophysiologic findings do not support CIDP or do not rule out other conditions
    • Failure of or contraindication to corticosteroids or IVIG is not demonstrated
    • No neurologist prescription or consultation
    • Required documentation of why IV Vyvgart cannot be used is absent or insufficient
    CIDP
    ConditionChronic inflammatory demyelinating polyneuropathy
    AbbreviationCIDP
    Required durationPersisted for longer than 2 months
    Required therapies: Pyridostigmine and corticosteroids must both have been tried and failed.
  3. Additional immunosuppressive therapies

    • Azathioprine: Tried and failed azathioprine.
    • Mycophenolate: Tried and failed mycophenolate.
    • Cyclosporine: Tried and failed cyclosporine.
    • Tacrolimus: Tried and failed tacrolimus.
  4. IV Vyvgart alternative: Medical record documentation shows clinical failure, intolerance, contraindication, or another valid medical reason why IV Vyvgart cannot be used.
  5. Initial therapy — CIDP

    Initial authorization for CIDP requires all of the following.

    CIDP criteria

    • Specialist and indication: Prescribed by or in consultation with a neurologist; Vyvgart Hytrulo is indicated or supported for treating chronic inflammatory demyelinating polyneuropathy (CIDP).
    • Disease duration: The condition has persisted for longer than 2 months.>2 months
    • Objective baseline assessment: Baseline strength and weakness are documented using an objective clinical measure, such as INCAT, MRC, 6-minute timed walking test, Rankin, or Modified Rankin.Objective baseline measure documented
    • Diagnostic support: Electrophysiologic findings support the diagnosis and rule out other conditions that may not respond to Vyvgart Hytrulo treatment.Supportive electrophysiologic findings
    • Prior therapy and IV Vyvgart alternative

      • Corticosteroids: Failure of or contraindication to corticosteroids.
      • IVIG: Failure of or contraindication to IVIG.
      • IV Vyvgart alternative: Medical record documentation shows clinical failure, intolerance, contraindication, or another valid medical reason why IV Vyvgart cannot be used.